Re-engineering of the duocarmycin structural architecture enables bioprecursor development targeting CYP1A1 and CYP2W1 for biological activity

Journal of Medicinal Chemistry

Volumn 56, Issue 15, 2013, Pages 6273-6277

  Sheldrake, Helen M ^a   Travica, Sandra ^b   Johansson, Inger ^b   Loadman, Paul M ^a   Sutherland, Mark ^a,d   Elsalem, Lina ^a   Illingworth, Nicola ^a   Cresswell, Alexander J ^a   Reuillon, Tristan ^a   Shnyder, Steven D ^a   Mkrtchian, Souren ^b   Searcey, Mark ^c   Ingelman Sundberg, Magnus ^b   Patterson, Laurence H ^a   Pors, Klaus ^a  

^a UNIVERSITY OF BRADFORD   (United Kingdom)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYP2W1; CYTOCHROME; CYTOCHROME P450 1A1; DUOCARMYCIN DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BIOLOGICAL ACTIVITY; CELL DEATH; CELL PROLIFERATION; CHEMOSENSITIVITY; CONTROLLED STUDY; DNA DAMAGE; DRUG CYTOTOXICITY; IC 50; NONHUMAN; PHARMACOPHORE; PROTEIN TARGETING;

ANIMALS; ANTINEOPLASTIC AGENTS; ARYL HYDROCARBON HYDROXYLASES; CELL LINE, TUMOR; CELL PROLIFERATION; CHO CELLS; CRICETINAE; CRICETULUS; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 ENZYME SYSTEM; DNA DAMAGE; DRUG SCREENING ASSAYS, ANTITUMOR; HEK293 CELLS; HUMANS; INDOLES; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSFECTION;

EID: 84881439741     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm4000209     Document Type: Article

References (25)

1. Tompkins, L. M.; Wallace, A. D. Mechanisms of cytochrome P450 induction J. Biochem. Mol. Toxicol. 2007, 21, 176-181
2. Wenzlaff, A. S.; Cote, M. L.; Bock, C. H.; Santer, S. K.; Schwartz, D. R.; Schwartz, A. G. CYP1A1 and CYP1B1 polymorphisms and risk of lung cancer among never smokers: a population-based study Carcinogenesis 2005, 26, 2207-2212
3. Leung, Y. K.; Lau, K. M.; Mobley, J.; Jiang, Z.; Ho, S. M. Overexpression of cytochrome P450 1A1 and its novel spliced variant in ovarian cancer cells: alternative subcellular enzyme compartmentation may contribute to carcinogenesis Cancer Res. 2005, 65, 3726-3734
4. Rodriguez-Antona, C.; Ingelman-Sundberg, M. Cytochrome P450 pharmacogenetics and cancer Oncogene 2006, 25, 1679-1691
5. Patterson, L. H.; Murray, G. I. Tumour cytochrome P450 and drug activation Curr. Pharm. Des. 2002, 8, 1335-1347
6. McFadyen, M. C.; Melvin, W. T.; Murray, G. I. Cytochrome P450 enzymes: novel options for cancer therapeutics Mol. Cancer Ther. 2004, 3, 363-371
7. Karlgren, M.; Gomez, A.; Stark, K.; Svard, J.; Rodriguez-Antona, C.; Oliw, E.; Bernal, M. L.; Ramon y Cajal, S.; Johansson, I.; Ingelman-Sundberg, M. Tumor-specific expression of the novel cytochrome P450 enzyme, CYP2W1 Biochem. Biophys. Res. Commun. 2006, 341, 451-458
8. Edler, D.; Stenstedt, K.; Ohrling, K.; Hallstrom, M.; Karlgren, M.; Ingelman-Sundberg, M.; Ragnhammar, P. The expression of the novel CYP2W1 enzyme is an independent prognostic factor in colorectal cancer-a pilot study Eur. J. Cancer 2009, 45, 705-712
9. Stenstedt, K.; Hallstrom, M.; Johansson, I.; Ingelman-Sundberg, M.; Ragnhammar, P.; Edler, D. The expression of CYP2W1: a prognostic marker in colon cancer Anticancer Res. 2012, 32, 3869-3874
10. Boger, D. L.; Johnson, D. S. CC-1065 and the duocarmycins: understanding their biological function through mechanistic studies Angew. Chem., Int. Ed. Engl. 1996, 35, 1438-1474
11. MacMillan, K. S.; Boger, D. L. Fundamental relationships between structure, reactivity, and biological activity for the duocarmycins and CC-1065 J. Med. Chem. 2009, 52, 5771-5780
12. Searcey, M. Duocarmycins-nature's prodrugs? Curr. Pharm. Des. 2002, 8, 1375-1389
13. Ghosh, N.; Sheldrake, H. M.; Searcey, M.; Pors, K. Chemical and biological explorations of the family of CC-1065 and the duocarmycin natural products Curr. Top. Med. Chem. 2009, 9, 1494-1524
14. Searcey, M.; Patterson, L. H. Resistance in cancer: a target for drug discovery Curr. Med. Chem.: Anticancer Agents 2004, 4, 457-460
15. Sutherland, M.; Gill, J.; Loadman, P. M.; Sheldrake, H.; Searcey, M.; Pors, K.; Shnyder, S. D.; Patterson, L. H. Antitumor activity of a duocarmycin analogue rationalised to be metabolically activated by cytochrome P450 1a1 in human transitional carcinoma of the bladder Mol. Cancer Ther. 2011, 12, 27-37
16. Pors, K.; Loadman, P. M.; Shnyder, S. D.; Sutherland, M.; Sheldrake, H. M.; Guino, M.; Kiakos, K.; Hartley, J. A.; Searcey, M.; Patterson, L. H. Modification of the duocarmycin pharmacophore enables CYP1A1 targeting for biological activity Chem. Commun. 2011, 47, 12062-12064
17. Parrish, J. P.; Kastrinsky, D. B.; Stauffer, F.; Hedrick, M. P.; Hwang, I.; Boger, D. L. Establishment of substituent effects in the DNA binding subunit of CBI analogues of the duocarmycins and CC-1065 Bioorg. Med. Chem. 2003, 11, 3815-38
18. Jin, W.; Trzupek, J. D.; Rayl, T. J.; Broward, M. A.; Vielhauer, G. A.; Weir, S. J.; Hwang, I.; Boger, D. L. A unique class of duocarmycin and CC-1065 analogues subject to reductive activation J. Am. Chem. Soc. 2007, 129, 15391-7
19. Tercel, M.; Atwell, G. J.; Yang, S.; Stevenson, R.; Botting, K.; Smith, E.; Anderson, R. F.; Denny, W. A.; Wilson, W. R.; Pruijn, F. B. Hypoxia-activated prodrugs: substituent effects on the properties of nitro seco -1,2,9,9a-tetrahydrocyclopropa[ c ]-benz[ e ]indol-4-one (nitroCBI) prodrugs of DNA minor groove alkylating agents J. Med. Chem. 2009, 52, 7258-7272
20. Karlgren, M.; Ingelman-Sundberg, M. Tumour-specific expression of CYP2W1: its potential as a drug target in cancer therapy Expert Opin. Ther. Targets 2007, 11, 61-67
21. Yoshioka, H.; Kasai, N.; Ikushiro, S.; Shinkyo, R.; Kamakura, M.; Ohta, M.; Inouye, K.; Sakaki, T. Enzymatic properties of human CYP2W1 expressed in Escherichia coli Biochem. Biophys. Res. Commun. 2006, 345, 169-174
22. Tan, B. S.; Tiong, K. H.; Muruhadas, A.; Randhawa, N.; Choo, H. L.; Bradshaw, T. D.; Stevens, M. F.; Leong, C. O. CYP2S1 and CYP2W1 mediate 2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole (GW-610, NSC 721648) sensitivity in breast and colorectal cancer cells Mol. Cancer Ther. 2011, 10, 1982-1992
23. Wang, K.; Guengerich, F. P. Bioactivation of fluorinated 2-aryl-benzothiazole antitumor molecules by human cytochrome P450s 1A1 and 2W1 and deactivation by cytochrome P450 2S1 Chem. Res. Toxicol. 2012, 25, 1740-1751
24. Bui, P. H.; Hankinson, O. Functional characterization of human cytochrome P450 2S1 using a synthetic gene-expressed protein in Escherichia coli Mol. Pharmacol. 2009, 76, 1031-1043
25. Yu, L.; Waxman, D. J. Role of cytochrome P450 in oxazaphosphorine metabolism. Deactivation via N -dechloroethylation and activation via 4-hydroxylation catalyzed by distinct subsets of rat liver cytochromes P450 Drug Metab. Dispos. 1996, 24, 1254-1262